We believe that by having a better understanding of genetic conditions, we will be able to develop better treatments. We have formed a team of experienced researchers and medical staff that is combining their experience and knowledge to uncover the causes of neurodevelopmental disorders and improve behavioral and medical treatment options.
Participating in ADMI studies allows our innovation & research centers to form a new outlook on the evaluation & treatment of children with special developmental needs.
Making Advances Possible (MAP) Protocol
The MAP Protocol is focused on collecting detailed information about health and development to better understand neurodevelopmental conditions. Participants may conduct additional speech, behavioral, developmental, and/or neurological tests outside of what they might do in a normal clinic visit.
Geisinger MyCode® Community Health Initiative
This Geisinger-wide study involves collecting blood, saliva (spit), and health information from thousands of Geisinger patients for use in future research studies. By studying the genes and up-to-date medical information of a patient, researchers will be able to better understand, treat, or prevent different medical conditions.
At ADMI and all across the country, children and adults with autism and their family members are joining the SPARK research study. The goal of SPARK is to build the largest autism research group in the nation and to speed up our understanding of the causes of autism and how it impacts those affected. Click below to join online!
The Genome to Brain Network (G2B)
The ability to detect genetic causes of developmental and psychiatric conditions, such as autism spectrum disorder, intellectual disability, epilepsy, and schizophrenia, is transforming the practice of medical genetics. Geisinger ADMI is leading an international strategy, the Genome-to-Brain Network (G2B), that aims to standardize and accelerate the clinical characterization of genetic causes of DBD, keeping pace with the rapid rate of gene discovery.